Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 6/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | SMURF1 | Q9HCE7 | 3/20 | 0.38 |
| ▸ | SMURF2 | Q9HAU4 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | CCR3 | P51677 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3531475 | 0.85 | CYP3A4 (0.36) | HSD11B1SMURF1CYP3A4CCR3 | |
| SCHEMBL3532712 | 0.84 | HSD11B1 (0.46) | HSD11B1MAPTMGLL | |
| SCHEMBL3528469 | 0.84 | HSD11B1 (0.45) | HSD11B1KMT2AMEN1SMURF1SMURF2 | |
| SCHEMBL3531511 | 0.84 | MAPT (0.40) | HSD11B1KMT2AMEN1MAPTMGLL | |
| SCHEMBL3531287 | 0.84 | HSD11B1 (0.38) | HSD11B1CYP3A4 | |
| SCHEMBL3533829 | 0.84 | L3MBTL1 (0.34) | HSD11B1SMURF1 | |
| SCHEMBL3533424 | 0.83 | LMNA (0.38) | HSD11B1KMT2AMEN1MAPTMGLL | |
| SCHEMBL3531172 | 0.83 | HSD11B1 (0.50) | HSD11B1KMT2AMEN1MAPTCYP3A4 | |
| SCHEMBL3533226 | 0.81 | ALDH1A1 (0.40) | MAPT | |
| SCHEMBL3531401 | 0.81 | MGLL (0.40) | KMT2AMEN1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652057-B2 | Pyrazolones as 11b-HSD1 inhibitors for diabetes | HOFFMAN-LA ROCHE INC. (US) | 2010-01-26 | — | — | US | disclosed |
| EP-1924562-A2 | PYRAZOLONE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007025880-A2 | PYRAZOLONE DERIVATIVES AS 11-BETA HSD1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049574-A1 | New pyrazolones as 11b-HSD1 inhibitors for diabetes | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049574-A1 | New pyrazolones as 11b-HSD1 inhibitors for diabetes | HSD11B1, HSD17B1, HSD17B7 | HSD11B1 1/4885KMT2A 4086/4885MEN1 1683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.